Physician profile
Ying Wang
NPI 1073259487
$2,111.91
in general payments reported to CMS, 2019-2025
11 companies · $409 in 2025
The $409 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $181 · 2023: $831 · 2024: $691 · 2025: $409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,663 · Education: $268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,663.18 |
| Education | $267.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $808.72 | 2023-2025 | Tremfya |
| Abbvie INC. | $393.32 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $306.96 | 2023-2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $149.25 | 2022-2023 | Ilumya |
| Novartis Pharmaceuticals Corporation | $120.17 | 2023-2025 | |
| Calliditas Therapeutics US INC. | $116.14 | 2022 | |
| Leo Pharma INC. | $90.61 | 2022-2025 | Anzupgo, Adbry |
| Helsinn Therapeutics (U.S.), INC. | $47.14 | 2022-2023 | Valchlor |
| Pfizer INC. | $38.11 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $21.11 | 2025 | Zoryve |
| Sanofi Pasteur INC. | $20.38 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ying Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.